Although in our previous work we investigated the potential of ex vivo expanded Treg in the presence of IL‐34 to inhibit GVHD in humanized NSG mice,9 here, we demonstrate the potential of using directly IL‐34 as an immunotherapy in vivo in human. This evidence concerns the gene IL34 and graft versus host disease.